Pharmaceutical Companies Look to Biotech Industry to Combat Losses from Expiring Patents
The Paragon Report Provides Stock Research on Achillion Pharmaceuticals and Keryx Biopharmaceuticals
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 04/24/12 -- Mergers and Acquisitions have been a hot topic in the Biotechnology Industry recently. Pharmaceutical giants face an unprecedented number of patent expirations for its pharmaceutical products between 2009 and 2013. It is apparent that pharmaceutical companies have begun to make strategic decisions to combat the anticipated losses. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Achillion Pharmaceuticals (NASDAQ: ACHN) and Keryx Biopharmaceuticals (NASDAQ: KERX).
Access to full reports can be found at:
According to a recent report by Dealogic, pharmaceutical deals totaled $18.5 billion globally this year, an increase of 5% from the same period last year. As larger companies continue to reduce spending on research and development they continue to look at smaller biotech companies to diversify their product lines. Mergers & Acquisitions allows bigger companies to acquire products and technologies that are already proven in the market place, avoiding the many risks associated with research and development.
On Thursday Biotechnology Company Human Genome Sciences rejected a $2.59 billion takeover bid from GlaxoSmithKline. The announcement comes just a day after Swiss pharmaceutical company Roche announced that it was abandoning its bid for U.S. biotech firm Illumina.
Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections.
Keryx Biopharmaceuticals recently announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis. This study is part of an ongoing Phase 3 program for ferric citrate in Japan for the treatment of hyperphosphatemia.
Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.04.2012 - 12:20 Uhr
Sprache: Deutsch
News-ID 138437
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Investment Services & Trading
Diese Pressemitteilung wurde bisher 150 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharmaceutical Companies Look to Biotech Industry to Combat Losses from Expiring Patents"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
